Fasano, 2000 - Google Patents
Isolation and13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with parkinson's diseaseFasano, 2000
View HTML- Document ID
- 7225670289787884490
- Author
- Fasano M
- Publication year
- Publication venue
- Movement Disorders
External Links
Snippet
Neuromelanin is a dark brown pigment suspected of being involved in the pathogenesis of Parkinson's disease. This pigment can be isolated from normal human substantia nigra by a procedure that includes an extensive proteolytic treatment. In this study we used such a …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Double et al. | Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins | |
| Bendheim et al. | Development of indole-3-propionic acid (OXIGON™) for alzheimer’s disease | |
| Fasano et al. | Modifications of the iron–neuromelanin system in Parkinson's disease | |
| Subramaniam et al. | The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid β-peptide (25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease | |
| Ahmad et al. | Ginkgo biloba affords dose‐dependent protection against 6‐hydroxydopamine‐induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences | |
| Götz et al. | The relevance of iron in the pathogenesis of Parkinson's disease | |
| Zecca et al. | Interaction of human substantia nigra neuromelanin with lipids and peptides | |
| Goemaere et al. | Peroxiredoxin distribution in the mouse brain with emphasis on neuronal populations affected in neurodegenerative disorders | |
| Avramovich‐Tirosh et al. | Therapeutic targets and potential of the novel brain‐permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease 1 | |
| Brown | ORGINAL ARTICLE Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence | |
| Zucca et al. | Neuromelanin of the human substantia nigra: an update | |
| Li et al. | Inhibition of α‐synuclein fibrillization by dopamine analogs via reaction with the amino groups of α‐synuclein: Implication for dopaminergic neurodegeneration | |
| Wakamatsu et al. | The structure of neuromelanin as studied by chemical degradative methods | |
| Esparza et al. | Aluminum‐induced pro‐oxidant effects in rats: protective role of exogenous melatonin | |
| Fleckenstein et al. | Rapid and reversible effects of methamphetamine on dopamine transporters | |
| Deng et al. | Melatonin antagonizes Mn-induced oxidative injury through the activation of keap1–Nrf2–ARE signaling pathway in the striatum of mice | |
| Ferrari et al. | Synthesis, structure characterization, and evaluation in microglia cultures of neuromelanin analogues suitable for modeling Parkinson’s disease | |
| Codrich et al. | Neuronal hemoglobin affects dopaminergic cells’ response to stress | |
| Aime et al. | Isolation and 13C‐NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with parkinson's disease | |
| Enochs et al. | Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy | |
| Liu et al. | Iron toxicity in organotypic cultures of hippocampal slices: role of reactive oxygen species | |
| Juan et al. | Tau pathology, metal dyshomeostasis and repetitive mild traumatic brain injury: an unexplored link paving the way for neurodegeneration | |
| Fasano et al. | Is neuromelanin changed in Parkinson’s disease? Investigations by magnetic spectroscopies | |
| Double et al. | New face of neuromelanin | |
| Fornstedt Wallin | Oxidation of dopamine and related catechols in dopaminergic brain regions in Parkinson’s disease and during ageing in non-Parkinsonian subjects |